Cuba’s agreement is specifically with the Roswell Park Institute, and CEO Candace Johnson says that she hopes to get approval for testing the drug within six to eight months.
To speed up the process with the FDA application, the Center for Molecular Immunology will give Roswell Park all of the documentation on how the drug is produced, its toxicity data, as well as results from past trials in Cuba. Johnson hopes to start clinical trials in a year.
Cancer vaccines to date have been very expensive, however, CimaVax is comparatively cheap to produce and store. It also has less toxicity and fewer side effects compared to other cancer vaccines.